One Wealth Advisors LLC Sells 152 Shares of Johnson & Johnson (NYSE:JNJ)

One Wealth Advisors LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 2.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,606 shares of the company’s stock after selling 152 shares during the quarter. One Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $909,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Naviter Wealth LLC lifted its position in Johnson & Johnson by 6.4% in the 3rd quarter. Naviter Wealth LLC now owns 19,747 shares of the company’s stock worth $3,200,000 after buying an additional 1,189 shares during the last quarter. Hengehold Capital Management LLC lifted its position in Johnson & Johnson by 2.4% in the third quarter. Hengehold Capital Management LLC now owns 24,668 shares of the company’s stock valued at $3,998,000 after purchasing an additional 582 shares during the last quarter. Probity Advisors Inc. lifted its position in Johnson & Johnson by 1.7% in the third quarter. Probity Advisors Inc. now owns 10,707 shares of the company’s stock valued at $1,735,000 after purchasing an additional 179 shares during the last quarter. Kowal Investment Group LLC lifted its position in Johnson & Johnson by 4.6% in the third quarter. Kowal Investment Group LLC now owns 10,339 shares of the company’s stock valued at $1,675,000 after purchasing an additional 451 shares during the last quarter. Finally, Cornerstone Wealth Management LLC lifted its position in Johnson & Johnson by 6.3% in the third quarter. Cornerstone Wealth Management LLC now owns 47,372 shares of the company’s stock valued at $7,677,000 after purchasing an additional 2,807 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $0.25 during midday trading on Thursday, reaching $164.53. 827,243 shares of the company’s stock traded hands, compared to its average volume of 7,015,466. The company has a market cap of $395.97 billion, a price-to-earnings ratio of 10.24, a P/E/G ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The stock has a 50 day moving average of $162.81 and a 200 day moving average of $154.59.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.66 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is 30.92%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, TD Cowen decreased their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.